DR. JACQUES P. TREMBLAY AWARDED CIHR FUNDING TO TREAT ALZHEIMER’S
SOVAR is proud to announce that Professor Jacques P. Tremblay of the CHU de Québec (Quebec University Hospital) Research Centre was awarded a grant totalling $159,931 from the Canadian Institutes of Health Research (CIHR) under its Proof of Principle Program (POP phase 1).
The funding will be used toward the advancement of a new method for treating Alzheimer’s disease based on gene therapy. In applying the CRISPR technology recently developed by the scientific community, Dr. Tremblay has demonstrated his ability to alter the gene of the amyloid precursor protein responsible for the disease.
The POP Program is very competitive and specifically addresses technologies that have a solid scientific foundation and show strong market potential.
The funding made possible by a close collaboration between Dr. Tremblay, SOVAR and Université Laval will allow the technology to be further developed, which should contribute to increase its value and steer it toward commercialization.